Current Landscape and Emerging Therapies in Hair Loss Treatment for Androgenetic Alopecia

Androgen hormones and signalling via the androgen receptor play a key role in regulating the hair cycle and are strongly implicated in the pathogenesis of androgenetic alopecia (AGA). CosmeRNA ARI (ARI, androgen receptor inhibitor) (Bioneer Corp, Seoul, South Korea), which utilises Self-Assembled Micelle Inhibitory RNA (SAMiRNATM) technology represents a distinct approach to treating AGA that is applied topically and selectively targets androgen receptor (AR) mRNA to downregulate overexpression of the androgen receptor. In clinical studies, inhibiting androgen receptor expression using SAMiRNA micelles was shown to be an effective approach to treating AGA that significantly increased hair growth. During interviews conducted by the European Medical Journal (EMJ), two leading experts in the field of hair loss, Sergio Vañó-Galván, Director of the Hair Disorders Unit at Ramón y Cajal University Hospital and Associate Professor of Dermatology at the University of Alcalá in Madrid, Spain, and Young-jin Park from the Yas Clinic, Khalifa City in the UAE, discussed the current and future therapeutic landscape in AGA, and considered the role of SAMiRNA as a promising new treatment approach.